Multiple biomedical imaging techniques are used in all phases of cancer management.
Imaging forms an essential part of cancer clinical protocols and is able to furnish …

In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in
breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art …

Although triple-negative breast cancer (TNBC) has been studied extensively in the oncology
and pathology literature, there are few reports on imaging features. Emerging data suggest …

The prospective multicenter ACRIN 6691 trial was designed to evaluate whether changes
from baseline to mid-therapy in a diffuse optical spectroscopic imaging (DOSI)–derived …

Purpose To evaluate positron emission tomography (PET) using [18F] fluorodeoxyglucose
(FDG) for prediction of histopathologic response early during primary systemic therapy of …

Imaging of tumour response to therapy has steadily evolved over the past few years as a
result of advances in existing imaging modalities and the introduction of new functional …

Clinical evidence regarding the value of 18 F-FDG PET for therapy responses assessment in
breast cancer is increasing. The objective of this study is to evaluate the accuracy of 18 F …

We combine diffuse optical spectroscopy (DOS) and diffuse correlation spectroscopy (DCS)
to noninvasively monitor early hemodynamic response to neoadjuvant chemotherapy in a …

Neoadjuvant chemotherapy (NAC) involves administration of chemotherapeutic agents to
patients with newly diagnosed breast cancer prior to definitive surgical treatment …

The aim of the present study was to investigate if 18F-fluorodeoxyglucose (18F-FDG)
positron emission tomography/computed tomography (PET/CT) outperforms conventional …